Drugs for attention deficit-hyperactivity disorder do not increase the mid-term risk of sudden death in children: a meta-analysis of observational studies

Luigi Janiri, Marianna Mazza, Fabrizio D'Ascenzo, Chiara Davico, Giuseppe Biondi-Zoccai, Giacomo Frati, Enrico Romagnoli, Bianca Bassi, Claudio Moretti, Fiorenzo Gaita

Risultato della ricerca: Contributo in rivistaArticolo in rivista

11 Citazioni (Scopus)

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurobehavioral condition that typically manifests in childhood and is characterized by a wide range of emotional, functional, and neurocognitive impairments that interfere with social and emotional quality of life. According to the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), the diagnosis is made by confirming numerous symptoms in the inattention domain or the hyperactivity–impulsivity domain or both. Stimulant medications have been demonstrated to be efficacious and are considered the first-line pharmacological therapy for ADHD. Because of the increasing recognition of ADHD as a chronic disorder, the use of medications for the treatment of this disease has considerably expanded over the last decade, becoming common also among adolescents and adults in addition to prepubertal children. Both stimulants and atomoxetine have cardiovascular effects with increase in heart rate and blood pressure.
Lingua originaleEnglish
pagine (da-a)4320-4321
Numero di pagine2
RivistaINTERNATIONAL JOURNAL OF CARDIOLOGY
Volume168
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • Attention deficit–hyperactivity disorder
  • Cardiovascular disease
  • Meta-analysis

Fingerprint Entra nei temi di ricerca di 'Drugs for attention deficit-hyperactivity disorder do not increase the mid-term risk of sudden death in children: a meta-analysis of observational studies'. Insieme formano una fingerprint unica.

Cita questo